A study at #ACR21 by Charite-University Medicine Berlin researchers suggests taking tumor necrosis factor inhibitor (TNFi) #biologics earlier in the course of disease could slow down spinal progression in #AxialSpondyloarthritis patients. https://t.co/lDkaMkOcez

#Uveitis is the most ⬆ freq xtra-articular manifestation in axSpA. What factors are assoc'd w/AAU attacks? 👁‍🗨Active disease 👁‍🗨History of AAU Bottomline: Treat axSpA, treat uveitis = better outcomes. @RheumNow #ACR21 abs1314 https://t.co/O0kHulwJoP

axSpA and Uveitis Uveitis 🔼 in HLA-B27; Disease duration; Latin American pts 🔽 in Psoriasis ⭐️Uveitis was not significantly different in axSpA vs pSpA Recurrent Uveitis 🔼disease duration and body mass index (BMI) Abst #1307 #ACR21 @Rheumnow https://t.co/QDg8tOPgir

Emerging Therapies in Spondyloarthritis: A Promising Pipeline by Dr. Olga Petryna (@DrPetryna ) #ACR21 https://t.co/9ggUAh0YJe https://t.co/WHpQp3GYBe

• https://bit.ly/3bNFYEf

Knowledge Bowl at #ACR21 ⭐️Which HLA allele confers an increased risk for anterior uveitis and inflammatory sacroillitis? ➡️HLA-B27 @RheumNow

My summary article on some of the many abstracts at #ACR21 on #WorkParticipation in #axSpA. Featured abstracts in this article: #0358 https://t.co/LrZYWqCuOm #0362 https://t.co/flL5MiqDL8 @RheumNow https://t.co/tu5L0yIVIV

• Work Participation in Patients with Axial Spondyloarthritis in Germany: Results…
• Achievement of Stringent Thresholds of Disease Control Is Associated with Reduc…
• Work participation in patients with axial spondyloarthritis | RheumNow

Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP